Wave Life Sciences Ltd. (WVE)
Market Cap | 368.50M |
Revenue (ttm) | 4.18M |
Net Income (ttm) | -152.90M |
Shares Out | 86.91M |
EPS (ttm) | -2.27 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 416,806 |
Open | 4.18 |
Previous Close | 4.18 |
Day's Range | 3.99 - 4.31 |
52-Week Range | 1.16 - 7.12 |
Beta | -0.87 |
Analysts | Buy |
Price Target | 8.16 (+92.45%) |
Earnings Date | Mar 22, 2023 |
About WVE
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin ... [Read more]
Financial Performance
In 2021, WVE's revenue was $40.96 million, an increase of 104.03% compared to the previous year's $20.08 million. Losses were -$122.25 million, -18.45% less than in 2020.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for WVE stock is "Buy." The 12-month stock price forecast is $8.16, which is an increase of 92.45% from the latest price.
News

Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2022 Financial Results on March 22, 2023
CAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battl...

Wave Life Sciences (WVE) Upgraded to Buy: Here's What You Should Know
Wave Life Sciences (WVE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

After Plunging -23.26% in 4 Weeks, Here's Why the Trend Might Reverse for Wave Life Sciences (WVE)
Wave Life Sciences (WVE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings e...

Wave Life Sciences to Present at the 2023 Virtual SVB Securities Global Biopharma Conference
CAMBRIDGE, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battli...

All You Need to Know About Wave Life Sciences (WVE) Rating Upgrade to Buy
Wave Life Sciences (WVE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

4 Drug Stocks That More Than Doubled This Year
We present four biotech stocks, AVEO, CABA, VRNA and WVE, which despite the current volatile market, have provided more than twice the returns in 2022.

Wave Life Sciences Provides Positive Update on Proof-of-Concept Study for WVE-N531 in Duchenne Muscular Dystrophy
53% mean exon skipping and

Wave Life Sciences (WVE) Up 26% on Collaboration With GSK
Wave Lifesciences (WVE) signs a four-year research collaboration with GSK to advance discovery and development of oligonucleotide therapeutics focusing on novel genetic targets

Wave, GSK enter strategic collaboration
Shares of Wave Life Sciences Ltd. WVE, -7.20% jumped about 17% in premarket trading on Tuesday after the company announced a four-year strategic collaboration with GlaxoSmithKline GSK, -0.72% to devel...

Wave Life Sciences and GSK Announce Collaboration to Drive Discovery and Development of Oligonucleotide Therapeutics Focusing on Novel Genetic Targets
Wave receives upfront payment of $170 million in cash and equity, also eligible to receive milestone payments and royalties

Wave Life Sciences (WVE) Reports Q3 Loss, Misses Revenue Estimates
Wave Life Sciences (WVE) delivered earnings and revenue surprises of 12.50% and 94.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Wave Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update
Announced positive update in third quarter from SELECT-HD trial in HD; single doses of WVE-003 appeared generally safe and well-tolerated and suggested allele-selective reduction of mHTT protein in CS...

Wave Life Sciences to Present at the Stifel 2022 Healthcare Conference
CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battli...

Wave Life Sciences to Webcast Conference Call of Third Quarter 2022 Financial Results on November 10, 2022
CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battli...

Wave Life Sciences (WVE) Soars 13.8%: Is Further Upside Left in the Stock?
Wave Life Sciences (WVE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price in...

Wave Life Sciences to Highlight Advancements from PRISM Platform at Upcoming Scientific Congresses
Six presentations and posters between OTS and ESGCT meetings will highlight Wave's oligonucleotide chemistry advancements as well as RNA editing and RNAi capabilities

Wave Life Sciences Highlights Therapeutic Potential for WVE-006 for Alpha-1 Antitrypsin Deficiency and Progress Bringing RNA Editing to the Clinic During Analyst and Investor Event
WVE-006 is the most advanced candidate for AATD designed to restore functional wild-type AAT protein and reduce Z-AAT protein aggregation with potential for disease modification in both lung and liver...

Wave Life Sciences to Present at Chardan's 6th Annual Genetic Medicines Conference
CAMBRIDGE, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battl...

Wave Therapeutics (WVE) Up on Update From Huntington's Study
Wave Therapeutics (WVE) provides a positive update from its ongoing phase Ib/IIa study evaluating one of its lead candidates, WVE-003, for Huntington's disease. Stock up.

Wave Life Sciences Announces Positive Update from Phase 1b/2a SELECT-HD Trial with Initial Results Indicating Allele-Selective Target Engagement with WVE-003 in Huntington's Disease
Single doses of WVE-003 appear generally safe and well-tolerated

Wave Life Sciences to Host Analyst and Investor Virtual Event, “Towards the Clinic: Spotlight on RNA Editing for AATD,” on September 28, 2022
Focus on WVE-006, a first-in-class RNA editing development candidate for AATD, and feature AATD expert presentation Focus on WVE-006, a first-in-class RNA editing development candidate for AATD, and f...

Wave Life Sciences (WVE) Reports Q2 Loss, Lags Revenue Estimates
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -10.71% and 88.46%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Wave Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update
WVE-006 announced as investigational development candidate for AATD with CTA submissions expected in 2023; first-in-class RNA editing candidate and most advanced program currently in development usin...

Wave Life Sciences to Webcast Conference Call of Second Quarter 2022 Financial Results on August 11, 2022
CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battli...

Wave Life Sciences Announces Pricing of $70.0 Million Underwritten Offering
CAMBRIDGE, Mass., June 14, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battli...